ClotCare: Blood Clots, Stroke, Heart Attack
Sunday, September 24, 2017
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

Stroke and Heart Attack: A Class Effect of COX 2 Inhibitors?

Henry I. Bussey, Pharm.D.
October 2004

Two leading authorities suggest that the increased risk of heart attack and stroke that resulted in the withdrawal of rofecoxib (Vioxx) is a class effect of the COX 2 inhibitors. Dr. Garret A. FitzGerald reviewed the available clinical data and explained how COX2 inhibitor-induced alterations in prostaglandin I-2 and thromboxane, together with potentiation of atherosclerosis, can lead to an increased risk of heart attack and stroke. Dr. Eric J. Topol offers additional comments supporting Dr. FitzGerald's position and significantly criticizes both the FDA and Merck for their delay in adequately addressing this risk. He further calls for a Congressional investigation into the role of the FDA and Merck in their handling of the available information.

References

1. FitzGerald, GA. Coxibs and Cardiovascular Disease. N Engl J Med. 351;17: 1709-11.

2. Topol EJ. Failing the Public Health — Rofecoxib, Merck, and the FDA. N Engl J Med. 351;17: 1707-09.

Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Rivaroxaban or Warfarin in Stable Coronary Artery Disease – Should the COMPASS Study Lead Us Back to the Future?

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2014 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-495-4335
Send comments to webmaster@clotcare.org.
Sunday, September 24, 2017